1. In Vivo
  2. >>Archive

Globus Prepared for Trek with $110m from Clarus-led Group

Clarus Ventures placed an unusually big bet for the orthopedics industry by leading a syndicate of private equity investors in a $110 million Series E round in Globus Medical Inc. But the four-year-old company is well ahead of its peers with more than $100 million in sales and a line of fusion products on the market. The company faces the challenge of introducing a new line of non-fusion and biomaterial products if it hopes to grow into the industry leader its investors expects it to be.

Investors in orthopedics traditionally have backed companies with technologies compelling enough to draw the interest of giants on the industry’s mountaintop—Medtronic Inc. ’s Medtronic Sofamor Danek , Johnson & Johnson ’s Depuy Spine Inc. , Synthes-Stratec ’s Synthes USA , Stryker Corp., and Zimmer Spine (a division of Zimmer Holdings Inc.’s Centerpulse AG)--controllers of 70% of the $4.3 billion US spine market. (See "The Hot Trend in Spine: Motion Preservation Mania," Medtech Insight, June 2007 Also see "The Hot Trend in Spine: Motion Preservation Mania" - Medtech Insight, 1 June, 2007..)

Last month, Clarus Ventures and a syndicate of private equity investors opted instead to invest heavily—unusually heavily for the orthopedics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success. 

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By Jo Shorthouse

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Execs On The Move: May 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.